J&J has a multi-year head start, but Gilead believes it can win market share by delivering a drug with better safety and at ...

A new report from Pitchbook suggests we’re in for a period of more sustainable investing, with VC firms continuing to create ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about ...

The candidate, named KT-621, is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster ...

The American Society for Clinical Oncology’s Annual Meeting for 2025 is, if nothing else, absolutely overwhelming and ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...

With updated Phase I/Ib data in hand, Arcus will launch a Phase III trial as it aims to compete with Merck, whose drug ...

In 2018, the FDA began an investigation into nitrosamine impurities in drugs that led to high-profile recalls for heartburn ...